Genprex Inc (NASDAQ:GNPX) has launched new branding for the upcoming oncology clinical trials combining its lead drug candidate REQORSA with AstraZeneca’s Tagrissoib and separately with Merck’s Keytruda for the treatment of non-small cell lung cancer (NSCLC).
These trials will use the brand name, “Acclaim,” which the company believes evokes the enthusiasm and hope these trials represent for NSCLC patients and the oncology community. Acclaim-1 will refer to the Tagrisso combination clinical trial, and Acclaim-2 will refer to the Keytruda combination clinical trial.
The idea is to encourage early exposure of Genprex’s clinical programs to patients, healthcare practitioners, clinical investigators, investors, employees and others. The company plans to initiate both Acclaim clinical trials in the first-half of 2021.
“We are enthusiastically preparing for our upcoming clinical trials and are excited to launch the adoption of this branding,” CEO Rodney Varner said in a statement. “We believe the Acclaim brand communicates our passion for providing hope to NSCLC patients for important new treatment options in the fight against this devastating disease and aligns us with the clinical, medical and patient communities.”
Acclaim-1 is a Phase 1/2 clinical trial using a combination of REQORSA with Tagrisso in patients with late-stage NSCLC with mutated epidermal growth factor receptors (EGFRs) whose disease progressed after treatment with Tagrisso. Acclaim-2 is a Phase 1/2 clinical trial using a combination of REQORSA with Keytruda in NSCLC patients who are low expressors (1 to 49%) of the protein, programmed death-ligand 1 (PD-L1).
Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel